Precision Medicine Can Deliver Affordable Care For Cancer Patients: Queens University Belfast Study
Are we missing a huge opportunity to deliver the best, most affordable care to cancer patients?

A new study examines the economic impact of precision oncology medicines compared to traditional oncology medicines.

Use of precision oncology medicines instead of traditional oncology medicines may help reduce the economic burden of cancer care. A study by Queen’s University Belfast has revealed that development of precision oncology medicines costs much less than traditional oncology medicines, and hence it can deliver affordable care for cancer patients.

The conclusion is based on a comprehensive study of the initial wave of precision oncology medicines, in which Belfast researchers compared the economic impact of precision oncology medicines and traditional oncology medicines.

According to the study results, research and development (R&D) cost for developing a precision oncology medicine (that is guided through clinical trials) is over $1 billion less than that of a “one size fits all” approach to cancer treatment.

Understand precision oncology and its benefits

Precision oncology focuses on developing medical treatments that target the molecular characteristics of a patient’s tumour, and identifying patients who are most likely to benefit from a particular medicine.

Senior author Professor Mark Lawler, Professor of Digital Health at Queen’s University Belfast, stated that shifting to a precision oncology Companion Diagnostic (CDx)-guided approach can deliver deliver affordable care for cancer patients. It will reduce the development cost and clinical trial attrition rates as well as spare patients from those treatments that are ineffective but may cause serious side effects.

By not deploying a CDx guided approach, we are missing a huge opportunity to deliver the best, most affordable care to our patients, he added.

The researchers strongly believe that using the “CDx guided approach” would increase the likelihood of cancer treatment being successful as well as cut treatment costs.

The findings of the Queen University Belfast study have been published in the journal of Pharmaceutical Policy and Practice.

For the study, Queen University Belfast collaborated with a team of precision healthcare economists and researchers from Salutem Insights Ltd, Diaceutics PLC and King’s College London. It is claimed to be the world’s first and most comprehensive study of the initial wave of precision oncology medicines in the marketplace.

Total Wellness is now just a click away.

Follow us on



window.addEventListener(‘load’, (event) => {
$(‘#commentbtn’).on(“click”,function(){
(function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = “//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.3”; fjs.parentNode.insertBefore(js, fjs);}(document, ‘script’, ‘facebook-jssdk’));
$(“.cmntbox”).toggle();
});
});



Source link

You May Also Like

Stress Management Tips for 2025 Board Exam Students

Exams are a challenge, but you are stronger! Manage stress, stay focused,…

Popeyes' New Chicken Sandwich Has the Internet Divided: 'Sounds Awful'

You like chicken and love tequila, but how do you feel about…

Osteopenia Explained: Gwyneth Paltrow’s Story and How to Protect Your Bones

Gwyneth Paltrow’s diagnosis of osteopenia at age 37 brought global attention to…

9 Unhealthiest Fast-Food Tacos To Stay Away From Right Now

One of the best ways to enjoy tacos is at your favorite…